Showing 1851-1860 of 2314 results for "".
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin
- Aurion Biotech Completes Enrollment In Phase 1/2 Clinical Trial of Allogeneic Cell Therapy Candidatehttps://modernod.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/Aurion Biotech announced that it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “Aurion Biotech is delighted that both enrollm
- Haag-Streit Launches 3D Imaging Option for the Imaging Module 910https://modernod.com/news/haag-streit-launches-3d-imaging-option-for-the-imaging-module-910/2482281/Haag-Streit announced the launch of the Imaging Module 910 3D. "To-date, ophthalmologists have been able to document slit lamp images, but only in 2D. The images presented in two dimensions lack depth, which limits the comprehensive visualization of the observed content. By enhanci
- AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Wet AMDhttps://modernod.com/news/asclepix-therapeutics-completes-enrollment-in-discover-trial-for-wet-amd/2482271/AsclepiX Therapeutics announced the completion of enrollment into the DISCOVER trial (NCT05859776) evaluating the safety and tolerability of three dose strengths of AXT107 (gersizangitide) for wet AMD. In the trial, 15 patients will receive either 125 µg (n=3), 250 &micr
- Aurion Biotech Announces Completion of Enrollment in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-completion-of-enrollment-in-phase-12-clinical-trial/2482253/Aurion Biotech announced it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f
- False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reportinghttps://modernod.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/The US Department of Justice (DOJ) has filed a complaint under the False Claims Act (FCA) against Regeneron alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea (aflibercept) by knowingly submitting false average sales price reports to CMS that excluded
- Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-positive-results-from-phase-3-trial-of-once-daily-ocs-01-for-treatment-of-inflammation-and-pain-following-cataract-surgery/2482221/Oculis announced positive results from the phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS annual meeting in Boston. Eric Donnenfeld, MD, presented the “Once Daily OCS-01, an OPTIREACH F
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- Bascom Palmer Outlines “Moon Shot” Whole Eye Transplant Research Initiativehttps://modernod.com/news/bascom-palmer-outlines-moon-shot-whole-eye-transplant-research-initiative/2482155/Thanks to a $1 million donation from a Florida philanthropist and humanitarian, the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, doctors and researche